Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Peroxide or compositions of or releasing gaseous oxygen or...
Patent
1994-10-20
1997-02-18
Mullis, Jeffrey C.
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Peroxide or compositions of or releasing gaseous oxygen or...
A61K 3340, A61K 4100, A61N 506
Patent
active
056039620
DESCRIPTION:
BRIEF SUMMARY
The invention relates to the use of aqueous solutions containing peroxodisulfate ions for the production of medicaments for the treatment of malignant cells of human and animal bodies. Furthermore, a process for the production of the agent and a device for carrying out the process are described.
Already in 1959 O. Warburg has noted in "Partielle Anaerobiose der Krebszellen und Wirkung der Rontgenstrahlen auf Krebszellen" ("Die Naturwissenschaften", vol. 2, 1959, pages 25 ff) that hydrogen peroxide can create a specific damage of cancer cells. Hydrogen peroxide acts at high concentrations as a cell poison. At low concentrations, in which it is found among others as an intermediate of the respiratory chain of the cells, it will be degraded by the enzyme catalase which is present in healthy cells. However, the enzyme catalase is present in cancer cells in only distinctly reduced concentration. Therefore, the therapeutic effect of X-rays is based upon the formation of hydrogen peroxide, which is degraded by catalase in healthy cells, whereas it has the desired damaging effect upon cancer cells. However, besides this effect, there are occuring side effects by using this therapy, which are based upon the known interaction processes of ionizing irradiation with organic tissue, and which are strongly straining the patient. The direct addition of hydrogen peroxide via the bloodstream to the cells to be treated, is impossible, because the catalase of the blood serum degrades the cell poison hydrogen peroxide before it reaches the cells to be cured.
From DE 35 28 379 A1 agents are known for the treatment of aqueous systems as well as for the regeneration of body cells, especially skin cells, which represent an aqueous medium containing peroxodisulfate ions. Among others, the agents are used for regeneration, i.e. for restoring body cells, particularly skin cells. The topical application is described for Psoriasis and diabetic gangrene.
DE 36 27 759 A1 discloses pharmaceutical compositions for the inactivation of bacterial endotoxins which contain a nontoxic water-soluble pharmaceutically acceptable peroxodiphosphate compound as an active substance.
From DERWENT-Abstracts 86-02462/04=PT 80 707 A is known, that derivatives of peroxodiphosphonic acid inhibit the development of tumor cells upon oral or systematic administration. The compound is added to a salt solution in a phosphate buffer at pH from 7 to 7,4, or in the form of coated tablets which do not disintegrate in the stomach but disintegrate by influence of the intestinal liquid.
On the other hand, the object of the present invention consists in providing and using a specifically acting agent for the treatment of malignant cells.
FIG. 1 depicts the preparation of the aqueous solutions in accordance with the present invention.
A primary embodiment of the present invention consists in the use of aqueous solutions containing peroxodisulfate ions for the preparation of medicaments for the treatment of malignant cells of the human or animal body.
A further embodiment of the present invention consists in the preparation of the aforementioned solutions which are available for instance by actinic irradiation of aqueous solutions containing anions of oxygen acids of sulfur, particularly sulfate ions and/or peroxodisulfate ions, having a pH value of 2 to 7.
The concentration of peroxodisulfate ions in the aqueous solutions to be applied in the present invention, are normally extremely low, because the peroxodisulfate ions are toxic at high concentration. Therefore, in another embodiment of the present invention, it is preferred that the solutions contain from 10.sup.-5 to 10.sup.-11 g/l, in particular from 10.sup.-7 to 10.sup.-11 g/l, peroxodisulfate ions. The concentration of peroxodisulfate ions should not exceed 10.sup.-4 g/l.
It can be achieved by agents of this kind, that the cells of the cell tissue to be treated, can be reached via the bloodstream, before they are degraded by endogenous enzymes like catalase. The desired degradation of the agents is not happening b
REFERENCES:
Chemical Abstracts, vol. 96, 1982, Columbus, Ohio, US; Abstract No. 173681h, p. 2, col. 1, Vannikov L. L. "Antihypoxic Effect of PSN," Tkanevaya Gipoksiya EEE Korrekts 1981, pp. 4-27.
Chemical Abstracts, vol. 67, 1967, Columbus, Ohio, US; Abstract No. 8451b, p. 787, col. 2, A. M. Lokshina et al. "The radiosensitizing Action of Sodium Persulfate," Med. Radiol., vol. 12, No. 2, 1967, pp. 81-83.
Derwent Publications Ltd., London, GB; AN 86026462(04) PT, A, 80 707 (Colgate Palmolive Co.,) 6 Dec. 1985.
Warburg, O., "Partielle Anaerobiose der Krebszellen und Workung der Rontgenstrahlen auf Krebszellen," Naturwissenschafen, 46:25-29 (1959).
Vannikov et al. "Antihypoxic effect of PSN", Tkanevaya Gipoksiya Ee Korrekts pp. 4-27 (1981).
Vannikov et al. translation of "Antihypoxic effect of PSN", Tkaneraya Gipoksiya Ee Korrekts pp. 4-27 (1981).
Lokshina et al., Med. Radiol 12(2), pp. 81-83 (1967).
Renschler Aloys
Schuster Dieter
Mullis Jeffrey C.
Renschler Aloys
LandOfFree
Use of aqueous solutions containing peroxobisulphate ions for th does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of aqueous solutions containing peroxobisulphate ions for th, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of aqueous solutions containing peroxobisulphate ions for th will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1600929